Lupin is currently trading at Rs. 987.90, up by 15.70 points or 1.61% from its previous closing of Rs. 972.20 on the BSE.
The scrip opened at Rs. 987.70 and has touched a high and low of Rs. 987.70 and Rs. 975.25 respectively.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1121.85 on 18-Sep-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 984.60 and Rs. 937.75 respectively. The current market cap of the company is Rs. 44080.49 crore.
The promoters holding in the company stood at 46.91%, while Institutions and Non-Institutions held 40.21% and 12.60% respectively.
Lupin has received approval for its Colesevelam Hydrochloride Tablets, 625 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Welchol Tablets, 625 mg, of Daiichi Sankyo, Inc. Colesevelam Hydrochloride Tablets (RLD: Welchol) had an annual sales of approximately $159 million in the U.S. (IQVIA MAT September 2020).
Colesevelam Hydrochloride Tablets, 625 mg, are indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia and to reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1537.05 |
Dr. Reddys Lab | 5872.60 |
Cipla | 1423.20 |
Zydus Lifesciences | 1008.80 |
Lupin | 1665.35 |
View more.. |